Jane Street Group LLC Sells 137,998 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Jane Street Group LLC lessened its position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 77.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,374 shares of the biotechnology company's stock after selling 137,998 shares during the period. Jane Street Group LLC's holdings in Rocket Pharmaceuticals were worth $508,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Covestor Ltd boosted its stake in Rocket Pharmaceuticals by 33,166.7% in the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after purchasing an additional 1,990 shares during the period. Signaturefd LLC boosted its position in shares of Rocket Pharmaceuticals by 319.8% in the fourth quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 3,745 shares during the period. Harbour Investments Inc. grew its stake in shares of Rocket Pharmaceuticals by 51.9% in the fourth quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock valued at $68,000 after acquiring an additional 1,840 shares in the last quarter. KBC Group NV grew its stake in shares of Rocket Pharmaceuticals by 159.6% in the fourth quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock valued at $69,000 after acquiring an additional 3,366 shares in the last quarter. Finally, Virtus ETF Advisers LLC grew its stake in shares of Rocket Pharmaceuticals by 40.4% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,656 shares of the biotechnology company's stock valued at $71,000 after acquiring an additional 1,628 shares in the last quarter. Institutional investors and hedge funds own 98.39% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on RCKT. TD Cowen reiterated a "hold" rating on shares of Rocket Pharmaceuticals in a research note on Tuesday. Jefferies Financial Group reiterated a "hold" rating on shares of Rocket Pharmaceuticals in a research report on Wednesday. Chardan Capital reduced their target price on Rocket Pharmaceuticals from $46.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday. Evercore ISI downgraded Rocket Pharmaceuticals from an "outperform" rating to an "in-line" rating and set a $5.00 price target for the company. in a research note on Friday. Finally, Leerink Partners reissued a "market perform" rating and issued a $8.00 target price (down from $37.00) on shares of Rocket Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $21.21.

Rocket Pharmaceuticals Trading Down 5.3%

Shares of RCKT stock traded down $0.14 during trading hours on Friday, hitting $2.48. 7,402,317 shares of the company's stock traded hands, compared to its average volume of 1,873,470. The stock has a market cap of $264.83 million, a PE ratio of -0.90 and a beta of 1.02. The stock's 50 day simple moving average is $6.20 and its 200 day simple moving average is $9.49. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. Rocket Pharmaceuticals, Inc. has a 12 month low of $2.19 and a 12 month high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.02. During the same period in the prior year, the business earned ($0.66) EPS. On average, sell-side analysts anticipate that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current year.

Insider Transactions at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider Kinnari Patel acquired 21,099 shares of the stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $4.70 per share, with a total value of $99,165.30. Following the transaction, the insider now owns 26,774 shares in the company, valued at approximately $125,837.80. The trade was a 371.79% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Gaurav Shah acquired 20,000 shares of the company's stock in a transaction dated Thursday, April 10th. The stock was acquired at an average cost of $5.08 per share, for a total transaction of $101,600.00. Following the completion of the purchase, the chief executive officer now directly owns 792,680 shares in the company, valued at $4,026,814.40. This trade represents a 2.59% increase in their ownership of the stock. The disclosure for this purchase can be found here. 24.76% of the stock is owned by corporate insiders.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.